Neurocrine Biosciences Reports Q3 2026 Revenue Up 41% to $1.12B, Raises INGREZZA Guidance

Executive Summary

On November 2, 2026, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) filed a Current Report on Form 8-K under Item 2.02 disclosing its financial results for the third quarter ended September 30, 2026. The company surpassed $1 billion in quarterly net product sales for the first time, driven by continued adoption of INGREZZA and commercial contributions from CRENESSITY and VYKAT XR.

Key Financial Highlights

• Total Revenues: $1,123 million, representing a 41% year-over-year increase compared to $795 million in Q3 2025.
• Product Revenue Breakdown:
  • INGREZZA: $801 million (+17% YoY vs. $687 million in Q3 2025), driven by double-digit volume growth and record TRx/NRx.
  • CRENESSITY: $211 million (+115% YoY vs. $98 million in Q3 2025) with ~80% reimbursement rates.
  • VYKAT XR: $107 million, contributing following the May 2026 acquisition of Soleno Therapeutics.
  • Other Revenues: $4 million (vs. $10 million in Q3 2025).
• GAAP Net Income & EPS: $207 million and $1.96 per diluted share, compared to $210 million and $2.04 per diluted share in Q3 2025.
• Non-GAAP Net Income & EPS: $347 million and $3.29 per diluted share, compared to $222 million and $2.17 per diluted share in Q3 2025.
• Cash Position: Cash, cash equivalents, and marketable securities stood at $790 million as of September 30, 2026 (down from $2,543 million at December 31, 2025, reflecting the Soleno Therapeutics acquisition).

Updated Full-Year 2026 Guidance

• INGREZZA Net Sales: Raised to $2,900 million – $2,925 million (previously $2,825 million – $2,875 million).
• GAAP R&D Expense: Maintained at $1,275 million – $1,325 million (Non-GAAP: $1,140 million – $1,190 million).
• IPR&D Expense: Updated to $34 million (previously $23 million).
• GAAP SG&A Expense: Lowered to $1,540 million – $1,560 million (previously $1,575 million – $1,600 million); Non-GAAP lowered to $1,290 million – $1,310 million (previously $1,325 million – $1,350 million).
• Amortization of Intangibles: Maintained at $85 million – $90 million.